South Korea · Delayed Price · Currency is KRW L&C BIO Co.,LTD Statistics
Total Valuation
L&C BIO Co.,LTD has a market cap or net worth of KRW 2.07 trillion. The enterprise value is 2.12 trillion.
| Market Cap | 2.07T |
| Enterprise Value | 2.12T |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
L&C BIO Co.,LTD has 26.97 million shares outstanding. The number of shares has increased by 4.72% in one year.
| Current Share Class | 26.97M |
| Shares Outstanding | 26.97M |
| Shares Change (YoY) | +4.72% |
| Shares Change (QoQ) | +1.89% |
| Owned by Insiders (%) | 23.97% |
| Owned by Institutions (%) | 10.38% |
| Float | 17.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 64.78 |
| PS Ratio | 21.14 |
| PB Ratio | 9.73 |
| P/TBV Ratio | 27.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 106.91 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.64 |
| EV / EBITDA | 119.48 |
| EV / EBIT | 226.98 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.64, with a Debt / Equity ratio of 0.41.
| Current Ratio | 0.64 |
| Quick Ratio | 0.32 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 4.86 |
| Debt / FCF | -28.66 |
| Interest Coverage | 1.64 |
Financial Efficiency
Return on equity (ROE) is -53.39% and return on invested capital (ROIC) is 3.72%.
| Return on Equity (ROE) | -53.39% |
| Return on Assets (ROA) | 1.34% |
| Return on Invested Capital (ROIC) | 3.72% |
| Return on Capital Employed (ROCE) | 4.30% |
| Weighted Average Cost of Capital (WACC) | 11.58% |
| Revenue Per Employee | 695.75M |
| Profits Per Employee | -958.47M |
| Employee Count | 141 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 0.99 |
Taxes
| Income Tax | -21.16B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +165.17% in the last 52 weeks. The beta is 1.38, so L&C BIO Co.,LTD's price volatility has been higher than the market average.
| Beta (5Y) | 1.38 |
| 52-Week Price Change | +165.17% |
| 50-Day Moving Average | 69,778.00 |
| 200-Day Moving Average | 63,992.75 |
| Relative Strength Index (RSI) | 52.84 |
| Average Volume (20 Days) | 406,442 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, L&C BIO Co.,LTD had revenue of KRW 98.10 billion and -135.14 billion in losses. Loss per share was -5,630.74.
| Revenue | 98.10B |
| Gross Profit | 53.99B |
| Operating Income | 9.60B |
| Pretax Income | -156.40B |
| Net Income | -135.14B |
| EBITDA | 18.02B |
| EBIT | 9.60B |
| Loss Per Share | -5,630.74 |
Balance Sheet
The company has 48.64 billion in cash and 87.49 billion in debt, with a net cash position of -38.86 billion or -1,440.70 per share.
| Cash & Cash Equivalents | 48.64B |
| Total Debt | 87.49B |
| Net Cash | -38.86B |
| Net Cash Per Share | -1,440.70 |
| Equity (Book Value) | 213.22B |
| Book Value Per Share | 8,183.11 |
| Working Capital | -88.75B |
Cash Flow
In the last 12 months, operating cash flow was 19.40 billion and capital expenditures -22.45 billion, giving a free cash flow of -3.05 billion.
| Operating Cash Flow | 19.40B |
| Capital Expenditures | -22.45B |
| Depreciation & Amortization | 8.42B |
| Net Borrowing | 23.66B |
| Free Cash Flow | -3.05B |
| FCF Per Share | -113.18 |
Margins
Gross margin is 55.03%, with operating and profit margins of 9.79% and -137.76%.
| Gross Margin | 55.03% |
| Operating Margin | 9.79% |
| Pretax Margin | -159.43% |
| Profit Margin | -137.76% |
| EBITDA Margin | 18.37% |
| EBIT Margin | 9.79% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.06%.
| Dividend Per Share | 50.00 |
| Dividend Yield | 0.06% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.72% |
| Shareholder Yield | -4.66% |
| Earnings Yield | -6.52% |
| FCF Yield | -0.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for L&C BIO Co.,LTD is 95,000.00, which is 23.54% higher than the current price. The consensus rating is "Buy".
| Price Target | 95,000.00 |
| Price Target Difference | 23.54% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 57.53% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on October 12, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Oct 12, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
L&C BIO Co.,LTD has an Altman Z-Score of 3.19 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.19 |
| Piotroski F-Score | 6 |